A committee of the European Medicines Agency has recommended the approval of Opdivo (nivolumab) for the treatment of people with advanced, inoperable, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC) who previously received a chemo regimen containing fluoropyrimidine and a platinum agent. The European Commission will review this opinion from the Committee for Medicinal Products for Human Use (CHMP) before making a decision. If approved, Opdivo will become the first immunotherapy available in Europe for a cancer…
You must be logged in to read/download the full post.
The post Committee Recommends EU Approval of Opdivo to Treat Advanced Esophageal Cancer appeared first on BioNewsFeeds.